➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Mallinckrodt
Dow
Express Scripts
Colorcon

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

LORATADINE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Loratadine, and when can generic versions of Loratadine launch?

Loratadine is a drug marketed by Bionpharma Inc, Marksans Pharma, Strides Pharma, Taro, Aurobindo Pharma Ltd, Lannett Co Inc, Perrigo, Pharm Assoc, Ranbaxy Labs Ltd, Teva, Wockhardt Bio Ag, Perrigo Pharma Intl, Sun Pharm, Actavis Labs Fl Inc, Glaxosmithkline, Rubicon, Tenshi, Apotex Inc, Granules, Guardian Drug, Mylan, Pld Acquisitions Llc, Sun Pharm Inds Ltd, Unique Pharm, Heritage Pharma, and P And L. and is included in forty NDAs.

The generic ingredient in LORATADINE is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.

Drug patent expirations by year for LORATADINE
Drug Prices for LORATADINE

See drug prices for LORATADINE

Drug Sales Revenue Trends for LORATADINE

See drug sales revenues for LORATADINE

Recent Clinical Trials for LORATADINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 2
National Cancer Institute (NCI)Early Phase 1
Rutgers, The State University of New JerseyEarly Phase 1

See all LORATADINE clinical trials

Medical Subject Heading (MeSH) Categories for LORATADINE
Paragraph IV (Patent) Challenges for LORATADINE
Tradename Dosage Ingredient NDA Submissiondate
CLARITIN HIVES RELIEF SYRUP;ORAL loratadine 020641
CLARITIN TABLET;ORAL loratadine 019658
CLARITIN HIVES RELIEF REDITAB TABLET, ORALLY DISINTEGRATING;ORAL loratadine 020704
CLARITIN HIVES RELIEF TABLET;ORAL loratadine 019658
CLARITIN REDITABS TABLET, ORALLY DISINTEGRATING;ORAL loratadine 020704
CLARITIN SYRUP;ORAL loratadine 020641

US Patents and Regulatory Information for LORATADINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pld Acquisitions Llc LORATADINE loratadine TABLET;ORAL 075209-001 Jan 21, 2003 OTC No No   Get Started for $10   Get Started for $10   Get Started for $10
Mylan LORATADINE loratadine TABLET;ORAL 076154-001 Aug 20, 2003 OTC No No   Get Started for $10   Get Started for $10   Get Started for $10
Sun Pharm Inds Ltd LORATADINE loratadine TABLET;ORAL 076134-001 Aug 18, 2003 OTC No No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim
Baxter
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.